BRITISH JOURNAL OF DERMATOLOGY Journal
Overview
publication venue for
- Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials. 190:836-845. 2024
- Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study. 189:392-399. 2023
- Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. 188:22-31. 2023
- The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies 2020
- The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. 181:733-742. 2019
- Continued treatment with secukinumab is associated with high retention or regain of response. 182:67-75. 2019
- Photodynamic therapy with methyl aminolaevulinate 80 mg g-1 for severe facial acne vulgaris: a randomized vehicle-controlled study. 174:770-777. 2016
- Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. 170:672-680. 2014
- Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. 163:334-339. 2010
- Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial 2023
- Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study 2021
- Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) 2018
- Early trends of disease improvement in adult patients with atopic dermatitis treated with dupilumab: real-world data from the PROSE registry 2021
- Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial 2017
Identity
International Standard Serial Number (ISSN)
- 0007-0963
Electronic International Standard Serial Number (EISSN)
- 1365-2133